Ulrich Spengler, managing director of altona Diagnostics GmbH, and his partners Markus Hess and the late Thomas Laue from the R & D department share a long-time experience in molecular diagnostics, especially in infectious diseases, dating back to their common years spent at the Bernhard Nocht Institute for Tropical Medicine in Hamburg, Germany.
altona Diagnostics is the culmination of over twenty years of their innovative achievements. These accomplishments include the first identification of mad cow disease (BSE) in Germany (2000) and the development of real-time PCR diagnostic test systems for their former company artus GmbH. Among these are the developments of the first worldwide commercially available molecular diagnostic test systems for the detection of SARS Corona virus (2003), Influenza A/B (H5N1, 2005), Swine Flu (nvH1N1, 2009), MERS-Corona virus (2013), Ebola virus (2014) and Zika virus (2016).
Part of the portfolio of diagnostic test systems for tropical and emerging infectious diseases has been developed in collaboration with the Bernhard Nocht Institute for Tropical Medicine, Hamburg, co-funded by the European Fund for Regional Development (ERDF) Hamburg.
Following this tradition the altona Diagnostics team actively develops and commercializes new molecular diagnostic assays – fast, flexible, reliable and close to the customer needs – as an answer to common and emerging infectious diseases.